SQZ Biotechnologies, a cell therapy company developing novel treatments for multiple therapeutic areas, announced that Armon Sharei, PhD, chief executive officer, will be presenting at the following upcoming virtual investor conferences
WATERTOWN, Mass.--(BUSINESS WIRE)-- SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that Armon Sharei, PhD, chief executive officer, will be presenting at the following upcoming virtual investor conferences:
Jefferies Virtual Healthcare Conference
Tuesday, June 2, 2020
Presentation Time: 3:30pm-3:55pm ET
Raymond James Human Health Innovations Conference
Wednesday, June 17, 2020
Cell Therapy Panel Time: 12:00pm ET
Dr. Sharei and Teri Loxam, chief financial officer will also be holding one on one meetings during the conferences.
About SQZ Biotech
SQZ Biotech is a privately held clinical stage company developing transformative cell therapy candidates for patients with cancer and other serious diseases. Our proprietary approach to cell engineering, Cell Squeeze®, physically squeezes cells through a microfluidic constriction to temporarily disrupt the cell membrane, allowing desired cargo to diffuse into the cell cytosol before the membrane reseals. We use this approach to deliver a broad range of biological material into diverse cell types to create multifunctional cell therapy candidates designed to direct specific immune responses. We believe Cell Squeeze® technology may allow us to create rapidly scalable cell therapies that leverage natural physiology to improve therapeutic efficacy with favorable safety and tolerability. The SQZ technology could provide treatment options with advantages for patients across many diseases. For more information please visit www.sqzbiotech.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200526005005/en/
SQZ:
Rebecca Cohen
Corporate and Investor Relations
rebecca.cohen@sqzbiotech.com
617-758-8672 ext. 728
Media:
Kate Contreras
Associate Director
kcontreras@w2ogroup.com
617-229-5960
Source: SQZ Biotechnologies
View this news release online at:
http://www.businesswire.com/news/home/20200526005005/en